A Study of ZW251 in Participants With Advanced Solid Tumors
Sponsored by Zymeworks BC Inc.
About this study
The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell non-small cell lung cancer (NSCLC), or germ cell tumors (GCT).
Part 1 (dose escalation) of the study will evaluate the safety and tolerability of ZW251 in HCC, squamous cell NSCLC, and GCT. Part 2 (dose optimization) of the study will further assess safety and potential anti-tumor activity of the ZW251 established recommended doses in HCC.
Where this study is enrolling
- Call 877-632-6789
MD Anderson Cancer Center
Houston, Texas
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
Who can participate
Inclusion criteria
- ✓Pathologically or cytologically confirmed diagnosis of HCC with evidence of locally advanced (unresectable, and ineligible for transplant) and/or metastatic disease. Noninvasive methods may be used to confirm diagnosis
- ✓Pathologically or cytologically confirmed diagnosis of squamous cell NSCLC with evidence of locally advanced (unresectable) and/or metastatic disease
- ✓Pathologically or cytologically confirmed diagnosis of GCT with evidence of yolk sac and/or choriocarcinoma predominant component and locally advanced (unresectable) and/or metastatic disease
- ✓Measurable disease per RECIST v1.1
- ✓Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
- ✓Liver function status of Child-Pugh Class A (for HCC only)
- ✓Adequate organ function
Exclusion criteria
- ✕Known additional malignancy that is progressing or that has required active treatment within the last year
- ✕History of hepatic encephalopathy within the past 6 months or requirement for medications to control encephalopathy
- ✕Participants with HCC experiencing main portal vein tumor invasion require sponsor approval for enrollment
- ✕Known gastrointestinal bleeding within 3 months
- ✕Acute or chronic uncontrolled renal disease, pancreatitis, or non-malignant liver disease
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.